Eleven Biotherapeutics Reports Fourth Quarter And Year-End 2014 Financial Results
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2014.
"We made significant progress advancing our pipeline of novel protein therapeutics for eye disease including our lead product candidate, EBI-005, which is in late-stage clinical development for dry eye disease and allergic conjunctivitis,” said Abbie Celniker, Ph.D., President and Chief Executive Officer.
Help employers find you! Check out all the jobs and post your resume.
"We made significant progress advancing our pipeline of novel protein therapeutics for eye disease including our lead product candidate, EBI-005, which is in late-stage clinical development for dry eye disease and allergic conjunctivitis,” said Abbie Celniker, Ph.D., President and Chief Executive Officer.
Help employers find you! Check out all the jobs and post your resume.